Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ANAB, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2026-12-12 | Quimilza (imsidolimab) (Vanda) | generalized pustular psoriasis (GPP) | BLA | 67% |
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| ANB032 | Atopic Dermatitis Eczema | Phase 2 · NCT05935085 | Terminated |
| Etokimab | Eosinophilic Asthma | Phase 2 · NCT03469934 | Completed |
| Mometasone Furoate Nasal Spray, 50 mcg | Chronic Rhinosinusitis | Phase 2 · NCT03614923 | Completed |
| Rosnilimab | Rheumatoid Arthritis | Phase 2 · NCT06041269 | Active not recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ANAB holds $212.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $17.7M/quarter from operations, an estimated runway of 36 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 40 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ANAB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Daniel Faga President, CEO, Director · +2.33M options |
Insider | 495,965 | 1.66% | 2026-03-25 |
| Paul F. Lizzul Chief Medical Officer · +71,242 options |
Insider | 42,088 | 0.14% | 2026-01-07 |
| John P. Schmid Director · +220,140 options |
Insider | 37,652 | 0.13% | 2026-06-15 |
| Dennis Mulroy CHIEF FINANCIAL OFFICER · +49,100 options |
Insider | 21,852 | 0.07% | 2026-01-07 |
| John A Orwin Director · +111,990 options |
Insider | 17,995 | 0.06% | 2026-09-15 |
| Eric J Loumeau CHIEF LEGAL OFFICER · +75,862 options |
Insider | 12,835 | 0.04% | 2026-02-11 |
| Hollings Renton Director · +230,140 options |
Insider | 10,995 | 0.04% | 2026-10-01 |
| Magda Marquet Director · +9,500 options |
Insider | 9,930 | 0.03% | 2026-01-15 |
Share count 29,895,244 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-10-19 | Jemperli | NDA | -15.4% | +5.6% | +4.6% |
| 2026-06-30 | — | NDA | +15.7% | +2.3% | +2.1% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANAB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →